urinary bladder neoplasms | sciencenewsnet.in

Breaking News

Potential of ginsenoside Rg1 to treat aplastic anemia via mitogen activated protein kinase pathway in cyclophosphamide-induced myelosuppression mouse model

Refining adipose-derived stem cell isolation for optimal regenerative therapy

Resilience and challenges: Evaluating the impact of stress conditions on mesenchymal stem cells across different passages

Melatonin-based priming of stem cells to alleviate oxidative stress

Effects of miR-214-5p and miR-21-5p in hypoxic endometrial epithelial-cell-derived exosomes on human umbilical cord mesenchymal stem cells

Efficacy of serum-free cultured human umbilical cord mesenchymal stem cells in the treatment of knee osteoarthritis in mice

Exosome-based strategy against colon cancer using small interfering RNA-loaded vesicles targeting soluble a proliferation-inducing ligand

Yes-associated protein-mediated melatonin regulates the function of periodontal ligament stem cells under oxidative stress conditions

Can We Avert the Looming Food Crisis of Climate Change?

Embedding Owner-Manager Values in the Small and Medium Sized Enterprise Context: A Lockean Conceptualisation

26 Nov, 2024

Sustained-release chemotherapy gives new option for frail patients with invasive bladder cancer

April 7, 2023 sarah JonasResearch Results

For patients with advanced bladder cancer who are medically unfit for standard treatment, a new intravesical (inside the bladder) chemotherapy delivery system called TAR-200 is safe and shows initial evidence of effectiveness, reports a study in the May issue of The Journal of Urology®, an Official Journal of the American Urological Association (AUA). The journal is published in the Lippincott portfolio by Wolters Kluwer.

Intravesical chemotherapy combination provides effective treatment alternative for high-risk non-muscle invasive bladder cancer

July 27, 2022 sarah JonasResearch Results

A combination of two intravesical chemotherapy drugs – gemcitabine and docetaxel – yields high response rates with good tolerability in patients with high-risk non-muscle-invasive bladder cancer (NMIBC), reports a study in The Journal of Urology®, an Official Journal of the American Urological Association (AUA). The journal is published in the Lippincott portfolio by Wolters Kluwer.